Leucemia Linfoblastica Acuta pediatrica: Blinatumomab approvato in monoterapia.

The European Commission has approved the use of blinatumomab as a monospecific therapy for the treatment of pediatric patients with acute lymphoblastic leukemia. This approval is a significant step forward, as immunotherapy represents a completely different approach than chemotherapy, with blinatumomab being a more manageable and less toxic drug. Dr. Rosanna Parasole, of Santobono Pausillipon Hospital in Naples, explained that the hospital is the largest pediatric hematology-oncology facility in Southern Italy, with approximately 209 diagnoses per year, divided between children and adolescents. Acute lymphoblastic leukemia is the most common oncological disease in pediatric age, accounting for approximately 30% of pediatric cancers, with 45-47 new diagnoses each year. The center is a single department divided into several complex facilities, including pediatric hematology, pediatric oncology, a bone marrow transplant center, a transfusion center with an umbilical cord blood bank, and a surgical oncology department. Dr. Parasole emphasized that, despite the Italian healthcare system being divided between the North, Center, and South, Naples represents excellence in the care of children with acute lymphoblastic leukemia, with the hospital attracting patients from across the Campania region. Currently, approximately 80% of children with this disease can be cured with chemotherapy alone, but the long-term side effects of this therapy can be very serious. Blinatumomab therefore represents a safer and less toxic alternative for these patients. #leukemia #ALL #blinatumomab #pediatriconcology English: The European Commission has approved the extension of Blinatumomab for use as monotherapy for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). This is a significant development because immunotherapy represents a completely different approach. Blinatumomab is a more manageable and less toxic drug. The video goes on to feature an interview with Dr. Rosanna Parasole of the Santobono Hospital in Naples, which is the largest oncology center in southern Italy and treats around 45 to 47 new cases of ALL each year. The hospital has a range of departments, including pediatric hematology, oncology, bone marrow transplantation, transfusion, and surgical oncology. The hospital provides care to 80% of children with ALL in the region. Despite the high success rate of chemotherapy in treating ALL, its short and long-term side effects can sometimes be serious. The use of Blinatumomab provides a more manageable alternative. ********************* 🔥 Follow us! Magazine: http://www.PianetaSalute.online IG:   / pianetasalute2.0   Twitter:   / pianetasalute   Facebook:   / pianetasalute   And subscribe to our YouTube channel!